BioPharmSignal logoBioPharmSignal

Biotech News

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

INmune Bio (INMB)INmune BioPartnership

BOCA RATON, Fla. and HOBOKEN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio's investigational treatment for Alzheimer's disease and other disease conditions.

Related news

IMMPImmutep Limited2026-10-14 12:00 EST

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

ATYRaTyr Pharma2026-10-19 11:00 EST

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

ALECAlector2026-10-05 11:00 EST

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

MREOMereo BioPharma2026-08-11 12:00 EST

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

INMBINmune Bio2026-09-14 11:00 EST

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

INMBINmune Bio2026-10-21 11:15 EST

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

HCMHUTCHMED2026-10-21 00:00 EST

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

REGNRegeneron Pharmaceuticals2026-10-01 05:00 EST

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

View all latest news

INmune Bio

Innate-Immune Therapeutics INmune Bio develops therapies that modify innate immune responses. Its programs span cell therapy, neuroinflammation and cancer biology. CORDStrom CORDStrom is an allogeneic umbilical-cord-derived stromal-cell therapy being developed for recessive dystrophic epidermolysis bullosa, a severe inherited skin...

Recent company news

INMBINmune Bio2026-10-21 11:15 EST

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

INMBINmune Bio2026-10-14 12:45 EST

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

INMBINmune Bio2026-10-06 13:00 EST

INmune Bio to Attend the 2026 Maxim Growth Summit

INMBINmune Bio2026-09-14 11:00 EST

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

INMBINmune Bio2026-09-09 12:00 EST

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

Stock data

Close
1.61 USD
Market cap
37.75M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States